TransMedics Raises Fy24 Revenue From $360M-$370M To $390M-$400M Vs $366.990M Est.
Portfolio Pulse from Benzinga Newsdesk
TransMedics has increased its FY24 revenue forecast from the range of $360M-$370M to $390M-$400M, surpassing the estimated $366.990M.
April 30, 2024 | 9:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TransMedics has revised its FY24 revenue outlook upwards, now expecting $390M-$400M, which is above the analyst estimate of $366.990M.
The upward revision of the FY24 revenue forecast by TransMedics indicates a stronger financial outlook than previously anticipated. This positive adjustment is likely to instill confidence among investors, potentially leading to an increase in the stock price in the short term. The surpassing of analyst estimates further underscores the company's robust performance and growth prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100